SIE

209

+4.73%↑

AIR.FR

163.22

+2.91%↑

ENR.DE

147.45

+7.08%↑

RHM

1,463.5

+0.21%↑

HO

237.7

+1.02%↑

SIE

209

+4.73%↑

AIR.FR

163.22

+2.91%↑

ENR.DE

147.45

+7.08%↑

RHM

1,463.5

+0.21%↑

HO

237.7

+1.02%↑

SIE

209

+4.73%↑

AIR.FR

163.22

+2.91%↑

ENR.DE

147.45

+7.08%↑

RHM

1,463.5

+0.21%↑

HO

237.7

+1.02%↑

SIE

209

+4.73%↑

AIR.FR

163.22

+2.91%↑

ENR.DE

147.45

+7.08%↑

RHM

1,463.5

+0.21%↑

HO

237.7

+1.02%↑

SIE

209

+4.73%↑

AIR.FR

163.22

+2.91%↑

ENR.DE

147.45

+7.08%↑

RHM

1,463.5

+0.21%↑

HO

237.7

+1.02%↑

Search

Teleperformance SE

Atvērts

SektorsRūpniecība

49.42 1.23

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

48.32

Max

51.26

Galvenie mērījumi

By Trading Economics

Ienākumi

-1M

248M

Pārdošana

-23M

5.1B

P/E

Sektora vidējais

6.064

61.065

Dividenžu ienesīgums

8.78

Peļņas marža

4.869

Darbinieki

446,716

EBITDA

99M

988M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+56.56% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

8.78%

2.23%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

42M

3B

Iepriekšējā atvēršanas cena

48.19

Iepriekšējā slēgšanas cena

49.42

Ziņu noskaņojums

By Acuity

80%

20%

387 / 406 Rangs Industrials

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Teleperformance SE Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. marts 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

2026. g. 23. marts 22:55 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

2026. g. 23. marts 21:51 UTC

Iegādes, apvienošanās, pārņemšana

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

2026. g. 23. marts 23:59 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. marts 23:59 UTC

Tirgus saruna

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

2026. g. 23. marts 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

2026. g. 23. marts 23:37 UTC

Tirgus saruna

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

2026. g. 23. marts 22:42 UTC

Tirgus saruna
Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 23. marts 22:42 UTC

Tirgus saruna
Galvenie ziņu notikumi

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

2026. g. 23. marts 22:40 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

2026. g. 23. marts 22:23 UTC

Tirgus saruna

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

2026. g. 23. marts 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

2026. g. 23. marts 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

2026. g. 23. marts 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

2026. g. 23. marts 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

2026. g. 23. marts 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

2026. g. 23. marts 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

2026. g. 23. marts 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

2026. g. 23. marts 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

2026. g. 23. marts 22:15 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

2026. g. 23. marts 22:08 UTC

Tirgus saruna

Ebos Needs to Reset Its Gearing Targets -- Market Talk

2026. g. 23. marts 21:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 23. marts 21:42 UTC

Tirgus saruna

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

2026. g. 23. marts 21:10 UTC

Galvenie ziņu notikumi

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 23. marts 20:50 UTC

Tirgus saruna
Peļņas
Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Teleperformance SE Prognoze

Cenas mērķis

By TipRanks

56.56% augšup

Prognoze 12 mēnešiem

Vidējais 80 EUR  56.56%

Augstākais 115 EUR

Zemākais 50 EUR

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Teleperformance SE — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

3

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

91.28 / 94.3Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Strong Bearish Evidence

Noskaņojums

By Acuity

387 / 406 Rangs Rūpniecība

Ziņu noskaņojums

Ļoti spēcīga liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Teleperformance SE

Teleperformance SE, together with its subsidiaries, engages in the customers consultancy services in France and internationally. The company operates in two segments, Core Services and Digital Integrated Business Services, and Specialized Services. The company offers customer relationship operations, technical support, technical assistance and customer acquisition services, management of business processes, back office and digital platform services, consulting, data analysis services, on-line interpretation, visa application management, health management services, and accounts receivable credit management services, and recruitment process outsource services. It also provides digital CX, trust and safety, artificial intelligence, video CX, metaverse, CX management, advanced analytics, business transformation consulting, technology as a service, collection service, interpretation and translation, and healthcare support services. The company serves automotive, energy and utilities, insurance, government, technology, travel and hospitality, and banking and financial services, as well as healthcare, media, retail and e-commerce, cargo, telecom, and video games industries. Teleperformance SE was incorporated in 1910 and is headquartered in Paris, France.
help-icon Live chat